Sat. October 10th 14:00 - 14:40 Room 2 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Keiun)

Prevention of metachronous gastric cancer after H. pylori eradication

Chair:

Y. Yamaoka

Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine

Invited Lecture-1

 

D. Y. Graham

Baylor College of Medicine

Fri. October 9th 14:00 - 14:40 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Management of Barrett's esophagus, dysplasia and esophageal adenocarcinoma

Chair:

H. Tajiri

President, Japan Gastroenterological Endoscopy Society

Invited Lecture-2

 

P. Sharma

Division of Gastroenterology and Hepatology, University of Kansas

Fri. October 9th 14:00 - 14:45 Room 9 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Kyokko)

Metabolic profile of liver disease - NASH and hepatitis C

Chair:

K. Koike

Department of Gastroenterology, The University of Tokyo

Invited Lecture-3

 

J. George

University of Sydney

Fri. October 9th 9:00 - 9:45 Room 9 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Kyokko)

Pathology of Nonalcoholic Steatohepatitis (NASH)

Chair:

Y. Nakanuma

Department of Diagnostic Pathology, Shizuoka Cancer Center

Invited Lecture-4

 

M. M. Yeh

Department of Pathology, University of Washington

Fri. October 9th 14:00 - 14:40 Room 8 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Zuiko)

Cancer and the systemic inflammatory response: Past, present and future

Chair:

K. Hirata

Department of Surgery, Surgical Oncology & Science, Sapporo Medical University

Invited Lecture-5

 

D. C. McMillan

Academic Unit of Surgery, College of Medical, Veterinary and Life Sciences, University of Glasgow

Sat. October 10th 11:20 - 12:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Epigenetic biomarkers in colorectal cancer

Chair:

M. Mori

Department of Surgery, Osaka University

Invited Lecture-6

 

A. Goel

Gastrointestinal Cancer Research Laboratory; Baylor Research Institute and Charles A. Sammons Cancer Center

Sat. October 10th 14:00 - 14:40 Room 9 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Kyokko)

Anglo-Japanese collaborations in hepatocellular carcinoma (HCC) research: Results and prospects

Chair:

K. Yanaga

Department of Surgery, The Jikei University School of Medicine

Invited Lecture-7

 

P. Johnson

Department of Molecular and Clinical Cancer Medicine, The University of Liverpool

Thu. October 8th 9:00 - 12:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Hepatocellular carcinoma: Molecular approaches for diagnosis, prognosis, and therapy

Chair:

N. Izumi

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital

Chair:

M. Sakamoto

Department of Pathology, Keio University School of Medicine

Discussant:

K.-H. Han

Yonsei Liver Center, Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine

Discussant:

M. Kudo

Department of Gastroenterology and Hepatology, Kinki University School of Medicine

IS-S1-Keynote Lecture

Hepatocellular carcinoma: Molecular approaches for diagnosis, prognosis, and therapy

K.-H. Han

Yonsei Liver Center, Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine

IS-S1-1_G

Evaluation of stem/maturational status in hepatocellular carcinoma

T. Yamashita

Department of Gastroenterology, Kanazawa University Hospital

IS-S1-2_G

Analysis of prognostic significance of hepatic progenitor cell marker-positive hepatocellular carcinoma

A. Tsuchiya

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University

IS-S1-3_H

Molecular and imaging factors associated with prognosis after culative RFA

Y. Yasui

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital

IS-S1-4_H

Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma

N. Nishida

Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine

IS-S1-5_S

Molecular pathogenesis and targeted therapy for major vascular invasiveness of hepatocellular carcinoma

S. Tanaka

Department of Molecular Oncology, Tokyo Medical and Dental University, Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University

IS-S1-6_S

Clinical importance of pathological basis and relevance to molecular subtypes in hepatocellular carcinoma

H. Okabe

Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University

IS-S1-7_H

Significance of connective tissue growth factor with the malignant grade of hepatocellular carcinoma and its potential for therapeutic target.

Y. Makino

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

IS-S1-8_H

Pin1 promotes HCC progression and predicts poor prognosis by regulating NF-κB-PPAR-γ axis

S. Kuboki

Department of General Surgery, Graduate School of Medicine, Chiba University

IS-S1-9_H

Des-γ-carboxy prothrombin (DCP) producing mechanism based on PARP-1 in hepatocellular carcinoma

T. Taniguchi

Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School

IS-S1-10_H

Serum N-glycan was useful for the prediction of the prognosis in patients with HCC

K. Nouso

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences

IS-S1-Special Remarks

 

H. Yano

Kurume University

Thu. October 8th 14:00 - 17:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Recent progress in IgG4-related pancreatobiliary diseases

Chair:

K. Okazaki

Department of Gastroenterology and Hepatology, Kansai Medical University

Chair:

S. Chari

Mayo Clinic

IS-S2-Keynote Lecture

Recent progress in the IgG4-RD in the pancreatobiliary system

S. Chari

Mayo Clinic

IS-S2-1_G

Molecular pathology of IgG4-related pancreatobiliary disease

Y. Zen

Department of Diagnostic Pathology, Kobe University

IS-S2-2_G

Amendments of the clinical diagnostic criteria for sclerosing cholangitis

T. Nakazawa

Department of Gastroenterology, Japanese Red Cross Nagoya Daini Hospital

IS-S2-3_G

Recent progress in the treatment of IgG4-related pancreatitis and sclerosing cholangitis -experiences from USA

S. Chari

Mayo Clinic

IS-S2-4_G

IgG4-related pancreatitis and sclerosing cholangitis - The UK Experience

G. J. Webster

University College London Hospitals

IS-S2-5_G

Recent progress in the IgG4-related pancreatobiliary diseases

L. Frulloni

Department of Medicine, Pancreas Center, University of Verona

IS-S2-6_G

Recent progress in the treatment of IgG4-related pancreatitis and sclerosing cholangitis:Experience from Korea

M.-H. Kim

Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center

IS-S2-7_G

Recent progress in the treatment of IgG4-related pancreatitis -Experience from Japan-

T. Kamisawa

Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital

IS-S2-8_G

Present status of IgG4-related sclerosing cholangitis in Japan -a nationwide survey-

A. Tanaka

Department of Medicine, Teikyo University School of Medicine

IS-S2-9_G

Prognosis and long-term outcomes of autoimmune pancreatitis

S. Kawa

Center for Health, Safety, and Environmental Management, Shinshu University

IS-S2-Special Remarks

 

T. Shimosegawa

Division of Gastroenterology, Tohoku University Graduate School of Medicine

Fri. October 9th 9:00 - 12:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Recent progression in drug-induced liver injury (DILI)

Chair:

Y. Matsuzaki

Tokyo Medical University Ibaraki Medical Center

Chair:

N. Kaplowitz

USC Keck School of Medicine

IS-S3-Keynote Lecture

Recent progression in drug-induced liver injury (DILI)

N. Kaplowitz

USC Keck School of Medicine

IS-S3-1_G

Progressin Drug Induced Liver Injury

R. J. Fontana

University of Michigan Medical School

IS-S3-2_G

Genetic susceptibility to Drug-induced Liver Injury (DILI)

G. P. Aithal

Nottingham Digestive Diseases Centre, University of Nottingham

IS-S3-6_G

Clinical DILI Networks: What lessons have we learnt? The European and Latin American Experience

R. J. Andrade

Department of Medicine and Gastroenterology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)

IS-S3-3_G

Recent status of DILI in Japan

H. Takikawa

Department of Medicine, Teikyo University School of Medicine

IS-S3-4_H

An assessment of DDW-J 2004 scoring and case database of drug-induced liver injury diagnosis in Japanese general hospitals

N. Mori

Department of Gastroenterology/Liver Center, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital

IS-S3-5_H

Possible contribution of TNFα producing T cells in drug-induced liver injury.

S. Asabe

Department of Gastroenterology, Saitama Medical Center, Jichi Medical University

Fri. October 9th 14:40 - 17:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Diagnosis and treatment of Barrett epithelium and cancer<Video>

Chair:

T. Endo

Sapporo Shirakaba-dai Hospital

Chair:

M. Fujishiro

Department of Endoscopy and Endoscopic Surgery, The University of Tokyo Hospital

Chair:

P. Sharma

Division of Gastroenterology and Hepatology, University of Kansas

Discussant:

Y. Tsuji

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo

Discussant:

Y. Arimura

Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine

IS-PD1-Keynote Lecture1

Four unique markers of Barrett's esophagus and lymph node metastasis of Barrett's carcinoma

K. Takubo

Research Team for Geriatric Pathology and Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

IS-PD1-Keynote Lecture2

Treatment of Barrett's esophagus related dysplasia and early cancer

B. L. A. M. Weusten

Department of Gastroenterology and Hepatology, St. Antonius Hospital

IS-PD1-1_E

Diagnosis and Treatment of Barrett's Epithelium and Cancer

K. Y. Ho

Department of Medicine, National University Health System, Singapore

IS-PD1-2_G

Endoscopic aspects of early Barrett cancer -Japanese and western perspectives-

K. Goda

Department of Endoscopy, The Jikei University School of Medicine

IS-PD1-3_E

Diagnosis and treatment of Barrett epithelium and cancer

R. Singh

The University of Adelaide

IS-PD1-4_E

Endoscopic treatment for superficial Barrett's esophageal adenocarcinoma: utility of magnifying NBI endoscopy and negative biopsy around the lesion for diagnosis of its extent.

T. Shimizu

Department of Gastroenterology, The Cancer Institute Hospital

IS-PD1-5_E

Diagnosis of the lateral extension of Barrett's adenocarcinoma under squamous epithelium

Y. Maeda

Department of Gastroenterology, Sendai City Medical Center

IS-PD1-6_G

Usefulness of optical coherence tomography for the evaluation of buried Barrett's mucosa in Barrett`s adenocarcinoma

K. Uno

Division of Gastroenterology, Tohoku University Hospital

IS-PD1-7_E

Usefulness of miniprobe EUS for the diagnosis of Barrett's esophageal cancer invasion

T. Shibata

Department of Gastroenterology, School of Medicine, Fujita Health University

IS-PD1-8_E

The treatment strategy of the superficial Barrett's esophageal cancer (SBEC).

Y. Kume

The Department of Esophageal and General Surgery, Tokyo Medical and Dental University

IS-PD1-9_E

A study of endoscopic features and treatment of superficial Barrett's adenocarcinoma

A. Matsui

Department of Gastroenterology, Toranomon Hospital

IS-PD1-10_E

Long term prognosis of Barrett's esophageal adenocarcinoma treated by ESD

A. Takahashi

Department of Endoscopy, Saku Central Hospital Advanced Care Center

Sat. October 10th 14:00 - 17:00 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Strategy of treatment for biliary stenosis<Video>

Chair:

K. Yasuda

Department of Gastroenterology, Kyoto Second Red Cross Hospital

Chair:

I. Maetani

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Ohashi Medical Center

Discussant:

T. Tsuyuguchi

Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University

Discussant:

H. Kawamoto

Department of Internal Medicine, Kawasaki Hospital, Kawasaki Medical School

IS-PD2-1_E

Comparison of fully and partially covered 6mm self-expanding metalic biliary stent for hilar malignant obstruction.

T. Yoshida

Deptartment of Gastroenterology, Aichi Cancer Center Central Hospital

IS-PD2-2_E

The suitable diameter of self-expandable metallic stent in bilateral endoscopic stent-in-stent deployment for malignant hilar biliary obstruction

I. Naitoh

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences

IS-PD2-3_E

Endoscopic balloon dilation using a short double-balloon enteroscopy was useful for treatment of choledochojejunal anastomotic stenosis

D. Uchida

Department of Gastroenterology, Okayama University Hospital

IS-PD2-4_E

Feasibility of short-type single-balloon enteroscopy for the initial management of suspected biliary stenosis in patients with surgically altered anatomy

K. Yane

Center for Gastroenterology, Teine-Keijinkai Hospital

IS-PD2-5_G

Strategy for the treatment of biliary anastomosis stricture in patients with surgically altered anatomy.

R. Tonozuka

Department of Gastroenterology and Hepatology, Tokyo Medical University

IS-PD2-6_E

EUS-guided antegrade biliary stenting for unresectable malignant biliary obstruction in patients with surgically altered anatomy: A single center prospective pilot study

T. Iwashita

First Department of Internal Medicine, Gifu University Hospital

IS-PD2-7_E

EUS guided biliary drainage for treatment of biliary obstruction

H. Imai

Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine

IS-PD2-8_E

Endoscopic treatment of biliary stenosis due to ampullary tumors with biliary extension

H.-P. Wang

Department of Internal Medicine, National Taiwan University Hospital

IS-PD2-9_E

Strategy of Treatment for Biliary Stenosis

D. W. Seo

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine

IS-PD2-10_E

The role of fully covered self-expandable metal of benign stent for treatment biliary strictures

R. Rerknimitr

Chulalongkorn University

IS-PD2-11_E

Wire-guided diathermic dilator for refractory bile duct strictures

H. Kawakami

Department of Gastroenterology and Hepatology, Hokkaido University Hospital

IS-PD2-12_E

Endoscopic Management of Biliary Strictures after Adult Living Donor Liver Transplantation with Duct-to-Duct Reconstruction

H. Kogure

Department of Gastroenterology, The University of Tokyo

Fri. October 9th 9:45 - 12:00 Room 9 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Kyokko)

Pathological features of Nonalcoholic Steatohepatitis (NASH)

Chair:

Y. Nakanuma

Department of Diagnostic Pathology, Shizuoka Cancer Center

Chair:

E. Hashimoto

Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University

Discussant:

M. M. Yeh

Department of Pathology, University of Washington

Discussant:

Y. Zen

Department of Diagnostic Pathology, Kobe University

IS-W1-1_H

Changes in the histopathologic criteria for diagnosis of nonalcoholic steatohepatitis: Historical perspective and future directions

Y. Ikura

Department of Pathology, Takatsuki General Hospital

IS-W1-2_H

Study of immunohistochemical biomarker for differentiating nonalcoholic steatohepatitis from alcoholic steatohepatitis.

T. Saito

Department of Hepatolgy, Kanazawa Medical University

IS-W1-3_H

Association of PNPLA3 with non-obese NASH.

Y. Honda

Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine

IS-W1-4_H

The histological course of nonalcoholic steatohepatitis: a longitudinal study of sequential liver biopsies

T. Kogiso

Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University

IS-W1-5_H

The expression of phosphatase and tensin homolog in non-B non-C hepatocellular carcinoma

K. Kon

Department of Gastroenterology, Juntendo University School of Medicine

IS-W1-6_H

Utility of laparoscopic findings in the diagnosis of nonalcoholic fatty liver disease

Y. Tokumoto

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine

IS-W1-7_G

The vicious cycle of ER stress and steatosis in NASH progression

H. Nakagawa

Department of Gastroenterology, The University of Tokyo

IS-W1-8_H

Phase 3 Results: Efficacy and Safety of Sebelipase in Patients with Lysosomal Acid Lipase Deficiency

K. Amano

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine

IS-W1-Special Remarks

 

T. Okanoue

Saiseikai Suita Hospital

Fri. October 9th 14:45 - 17:00 Room 9 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Kyokko)

New trends in diabetes mellitus and liver diseases

Chair:

S. Kaneko

Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences

Chair:

S. Watanabe

Department of Gastroenterology, Juntendo University School of Medicine

Discussant:

J. George

University of Sydney

Discussant:

T. Kadowaki

Department of Diabetes and Metabolic Diseases, The University of Tokyo

IS-W2-1_H

Regulation of glucose metabolism and systemic insulin sensitivity by hepatokines

H. Misu

Department of Comprehensive Metabology, Kanazawa University Graduate School of Medical Sciences,JST PRESTO

IS-W2-2_H

Immuno-nutritional approach for impaired glucose tolerance in metabolic steatohepatitis through modulation of Kupffer cell function

K. Ikejima

Department of Gastroenterology, Juntendo University School of Medicine

IS-W2-3_H

Obesity exacerbates lipotoxicity induced by saturated fatty acid

Y. Ogawa

Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine

IS-W2-4_H

Enhanced expression of Rubicon inhibits autophagy and promotes apoptosis by increasing endoplasmic reticulum stress in nonalcoholic fatty liver disease.

S. Tanaka

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

IS-W2-5_H

MK-0626, a selective DPP-4 inhibitor, ameliorates hepatic steatosis in ob/ob mice.

T. Ohyama

Department of Medicine and Molecular Science of Gunma University

IS-W2-6_H

The efficacy of a SGLT2 inhibitor for the treatment of NASH

A. Morishita

Department of Gastroenterology and Neurology, Kagawa University

IS-W2-7_H

Sitagliptin can be effective drug for hepatic iron metabolism

S. Fukunishi

Second Department of Internal Medicine, Osaka Medical College

IS-W2-8_H

Ipragliflozin, a sodium glucose cotransporter2 inhibitor, ameliorates liver fibrosis development in diabetic OLETF rats.

N. Nishimura

The Third Department of Internal Medicine, Nara Medical University

IS-W2-9_G

Impact of Diabetes Mellitus on Frequency and Severity of Hepatic Encephalopathy in Liver Cirrhosis

M. U. Makki

Services Hospital

IS-W2-10_H

Effects of Dipeptidyl Peptidase 4 inhibitor on Tumor Progression and Nrf2 Expression in a Mouse Model of Non-alcoholic Steatohepatitis-related Hepatocellular Carcinoma

T. Kawaguchi

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine

IS-W2-11_H

Variants in PNPLA3 and JAZF1 are associated with susceptibility to HCC development in T2DM patients without viral hepatitis

M. Ueyama

The Research Center for Hepatitis and Immunology, NCGM

IS-W2-12_H

Characteristics of Non-B Non-C hepatocellular carcinoma and lifestyle related diseases as its risk factors

K. Akahoshi

Hepatobiliary Pancreatic Surgery, Tokyo Medical and Dental University

IS-W2-Special Remarks

 

T. Kadowaki

Department of Diabetes and Metabolic Diseases, The University of Tokyo

Sat. October 10th 9:00 - 11:20 Room 6 (Grand Prince Hotel New Takanawa International Convention Center PAMIR / Aoba)

Up-to-date therapies in IBD

Chair:

A. Sugita

Inflammatory Bowel Disease Center, Yokohama Municipal Citizen's Hospital

Chair:

Y. Suzuki

Department of Internal Medicine, Sakura Medical Center, Toho University

Discussant:

T. Hisamatsu

Third Department of Internal Medicine, Kyorin University School of Medicine

Discussant:

M. Itabashi

Department of Surgery 2, Tokyo Women's Medical University

IS-W3-1_S

Optimizing biological therapy in IBD

M. Ferrante

Department of Gastroenterology, University Hospitals Leuven

IS-W3-2_S

Stem cell treatment for Crohn's anal fistulas refractory top conventional surgery

K. J. Park

Department of Surgery, Seoul National University College of Medicine

IS-W3-3_G

The predictive factor regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing

T. Yoshino

Division of Gastroenterology and Hepatology, Kitano Hospital

IS-W3-4_G

Treatment strategy of ulcerative colitis using fecal immunochemical test

S. Hiraoka

Department of Gastroenterology and Hepatology, Okayama University

IS-W3-5_G

The Early Response to Tacrolimus is likely to be a Predictor of the Long-term Outcome in the Patients with Ulcerative Colitis.

K. Takeuchi

Department of Internal Medicine, Sakura Medical Center, Toho University

IS-W3-6_G

Salvage therapy for corticosteroid-refractory ulcerative colitis patients: Results from the real-life clinical practice

K. Matsuoka

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University

IS-W3-7_G

Antiviral agents is not required in active ulcerative colitis patients with CMV reactivation

M. Naganuma

Department of Gastroenterology and Hepatology, Keio University

IS-W3-8_G

Does Pre-operative Multiple Immunosuppressive Therapy Associate with Surgical Site Infection in Surgery for Ulcerative Colitis?

M. Uchino

Inflammatory Bowel Disease Surgery, Hyogo College of Medicine

IS-W3-9_S

Outcomes and risk factor of postoperative complications in emergent operations for ulcerative colitis

T. Araki

Department of Gastrointestinal and Pediatric Surgery, Mie University

IS-W3-10_G

The relationship between pharmacokinetics of adalimumab and mucosal healing in patients with Crohn's disease.

Y. Morita

Department of Medicine, Shiga University of Medical Science

IS-W3-11_G

The optimization of adalimumab treatment strategy in patients with Crohn's disease using endoscopy and serum trough concentration.

N. Kamata

Department of Gastroenterology, Osaka City University

IS-W3-12_S

Prognosis of adominoperineal resection for severe anorectal Crohn's disease

K. Koganei

Inflammatory Bowel Disease Center, Yokohama Municipal Citizen's Hospital

IS-W3-Special Remarks

 

T. Fukushima

Matsushima Clinic